Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Sandoz International GmbH
Sandoz International GmbH
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Optimising RNA production for faster and cheaper pharmaceutical manufacturing
RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Sustainability
Sandoz and Teva achieve independent certification for steps to minimise antimicrobial resistance risk
Certification demonstrates their commitment to protecting people and the planet
Manufacturing
Sandoz opens new packaging centre in Stryków, Poland
The generics division of Novartis has invested €42m in the project
Pharmaceutical
Nick Haggar of Sandoz to become new EGA President
Takes up the role on 8 October
Media
Asia and Latin America will drive biosimilars growth in next decade, says Visiongain
Established players will focus on monoclonal antibodies and licensing deals
Ingredients
Sandoz begins clinical trial of biosimilar rituximab
Aims to demonstrate the bioequivalence of the monoclonal antibody
Regulatory
FDA approves first generic version of Lovenox
Sanofi-aventis has reservations about Sandoz drug for treating DVT
Finance
Sandoz to acquire Oriel Therapeutics
Deal will give Sandoz rights to portfolio of respiratory products targeting asthma and COPD
Subscribe now